Combinations ; Fluphenazine / Nortryptylline- See below
Dosage ; 12.5mg, then 12.5-100mg after 4-7 days repeated at the interval of 14-35 days
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Deca | Antlantic Laboratories Corp. ltd | Medipharm Sales Ltd | 25mg | 1ml | Injection | per vial | KES 75.00 |
| Fludecan | Sigma Laboratories Limited | Sai Pharmaceuticals Ltd. | 25mg | 5ml | Injection | per vial | KES 400.00 |
| Fluphenazine | Rotex Medical | Twokay Chemicals Ltd | 25mg | 1 | Injection | per vial | KES 125.00 |
| Prolinate | Sunlight International Trading (Africa) Co., Ltd | Harley's Limited | 25mg | 5ml | Injection | per vial | KES 780.00 |
|
Fluphenazine More info |
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug Indication | A depot injection for maintenance therapy in Schizophrenia and other psychoses. | ||||||||||||||||||||
| Precautions | Blood dyscrasia; cardiovascular and hepatic disorders; phaeochromocytoma; surgery; convulsions. | ||||||||||||||||||||
| Contra-Indications | Hepatic impairment; brain damage; large hypnotic doses; blood disorders; comatose; severe depressed patients; Parkinsonism. | ||||||||||||||||||||
| Side Effects | Extrapyramidal symptoms, drowsiness, insomnia, nightmare, tardive dyskinesia, hypothermia, apathy, pallor, convulsions, anti-muscarinic symptoms, nasal congestion, sudden death, ECG changes, SLE-like syndrome, blood dyscrasia, corneal and lens opacity, skin and eye pigment deposit. | ||||||||||||||||||||
| Dosage | 12.5mg, then 12.5-100mg after 4-7 days repeated at the interval of 14-35 days. | ||||||||||||||||||||
| Special Information | Exceptions: Less sedating; less anti-muscarinic symptoms, more extrapyramidal effects | ||||||||||||||||||||
| Pregnancy Category | Category C | ||||||||||||||||||||
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible | ||||||||||||||||||||
| Drug Category | DRUGS ACTING ON CNS | ||||||||||||||||||||
| Drug Sub-Category | Hypnotics, sedatives & tranquilizers
Use Management of manifestations of psychotic disorders and schizophrenia; depot formulation may offer improved outcome in individuals with psychosis who are nonadherent with oral antipsychotics Use - Unlabeled/Investigational Psychosis/agitation related to Alzheimer's dementia Adverse Reactions Significant Frequency not defined. Cardiovascular: Tachycardia, fluctuations in blood pressure, hyper-/hypotension, arrhythmia, edema Central nervous system: Parkinsonian symptoms, akathisia, dystonias, tardive dyskinesia, dizziness, hyper-reflexia, headache, cerebral edema, drowsiness, lethargy, restlessness, excitement, bizarre dreams, EEG changes, depression, seizure, NMS, altered central temperature regulation Dermatologic: Dermatitis, eczema, erythema, itching, photosensitivity, rash, seborrhea, skin pigmentation, urticaria Endocrine & metabolic: Menstrual cycle changes, breast pain, amenorrhea, galactorrhea, gynecomastia, libido changes, prolactin increased, SIADH Gastrointestinal: Weight gain, appetite loss, salivation, xerostomia, constipation, paralytic ileus, laryngeal edema Genitourinary: Ejaculatory disturbances, impotence, polyuria, bladder paralysis, enuresis Hematologic: Agranulocytosis, leukopenia, thrombocytopenia, nonthrombocytopenic purpura, eosinophilia, pancytopenia Hepatic: Cholestatic jaundice, hepatotoxicity Neuromuscular & skeletal: Trembling of fingers, SLE, facial hemispasm Ocular: Pigmentary retinopathy, cornea and lens changes, blurred vision, glaucoma Respiratory: Nasal congestion, asthma Contraindications Hypersensitivity to fluphenazine or any component of the formulation (cross-reactivity between phenothiazines may occur); severe CNS depression; coma; subcortical brain damage; in patients receiving large doses of hypnotics; blood dyscrasias; hepatic disease Dosing: Adult Psychosis: Oral: Initial: 2.5-10 mg/day in divided doses at 6- to 8-hour intervals; Maintenance: 1-5 mg/day; Note: Some patients may require up to 40 mg/day for symptom control (long-term safety of higher doses not established) PORT guidelines: Acute therapy: 6-20 mg/day for up to 6 weeks; Maintenance: 6-12 mg/day (Buchanan, 2009) I.M. (hydrochloride): Initial: 1.25 mg as a single dose; depending on severity and duration, may need 2.5-10 mg/day in divided doses at 6- to 8-hour intervals (4 mg I.M. fluphenazine HCl is approximately equivalent to 10 mg oral fluphenazine HCl ); use caution with doses >10 mg/day; once symptoms stabilized, transition to oral maintenance therapy Long-acting maintenance injections (decanoate): I.M., SubQ (decanoate): Initial: 12.5-25 mg every 2-4 weeks; response may last up to 6 weeks in some patients; titrate dose cautiously, if doses >50 mg are needed, increase in 12.5 mg increments (maximum dose: 100 mg) Conversion from hydrochloride dosage forms to decanoate I.M.: 12.5 mg of decanoate every 2-4 weeks is approximately equivalent to 10 mg of oral hydrochloride/day; Note: Clinically, an every-2-week interval is frequently utilized PORT guidelines: 6.25-25 mg every 2 weeks (Buchanan, 2009) Dosing: Geriatric Oral: Initial: 1-2.5 mg daily; titrated gradually based on patient response. Dosing: Renal Impairment Use with caution; not dialyzable (0% to 5%) Fluphenazine / Nortryptylline
|
||||||||||||||||||||